Challenges and advances in infection control of hematopoietic stem cell transplant recipients

Infectious Disorders - Drug Targets

Volumn 11, Issue 1, 2011, Pages 18-26

  Magauran, Claire E ^a   Salgado, Cassandra D ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Infection control; Oncology; Stem cell transplant

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIFUNGAL AGENT; ATOVAQUONE; COTRIMOXAZOLE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; ITRACONAZOLE; PENTAMIDINE; PNEUMOCOCCUS VACCINE; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VORICONAZOLE;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; BACILLI; BLOODSTREAM INFECTION; CELLULAR IMMUNITY; CLEANING; CLOSTRIDIUM DIFFICILE; DIARRHEA; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAND WASHING; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES VIRUS INFECTION; HOSPITAL INFECTION; HOSPITAL PERSONNEL; HUMAN; IMMUNOGLOBULIN DEFICIENCY; INFECTION CONTROL; LISTERIOSIS; LOW DRUG DOSE; MEDICAL RESEARCH; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUTH HYGIENE; MULTIDRUG RESISTANT GRAM NEGATIVE BACILLI; MYCOSIS; NEUTROPENIA; NOCARDIOSIS; PATIENT SELECTION; PNEUMONIA; RISK ASSESSMENT; TOXOPLASMOSIS; URINARY TRACT INFECTION; VACCINATION; VANCOMYCIN RESISTANT ENTEROCOCCUS;

EID: 79551621941     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611794407764     Document Type: Article

References (69)

1. Copelan, E.A. Hematopoietic stem-cell transplantation. N. Engl. J. Med., 2006, 354(17), 1813-1826.
2. CIBMTR Summary Slides, http://www.cibmtr.org/SERVICES/Observational_Research/Summary_Slides/index.html [Accessed 11/23/09].
3. Leather, H.L.; Wingard, J.R. Infections following hematopoietic stem cell transplantation. Infect. Dis. Clin. N. Am., 2001, 15, 483-520.
4. Krüger, W.; Rüssmann, B.; Kröger, N.; Salomon, C.; Ekopf, N.; Elsner, H-A.; Kaulfers, P-M.; Mack, D.; Fuchs, N.; Dürken, M.; Kabisch, H.; Erttmann, R.; Zander, A.R. Early infections in patients undergoing bone marrow or blood stem cell transplantation - a 7 year single centre investigation of 409 cases. Bone Marrow Transplant., 1999, 23, 589-597.
5. Kernan, N.A.; Bartsch, G.; Ash, R.C.; Beatty, P.G.; Champlin, R.; Filipovich, A.; Gajewski, J.; Hansen, J.A.; Henslee-Downey, J.; McCullough, J.; McGlave, P.; Perkins, H.A.; Phillips, G.L.; Sanders, J.; Stroncek, D.; Donnall Thomas, E.; Blume, K.G. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N. Engl. J. Med., 1993, 328, 593-602.
6. Wingard, J.R. Opportunistic infections after blood and marrow transplantation. Transpl. Infect. Dis., 1999, 1(1), 3-20.
7. Tomblyn, M.; Chiller, T.; Einsele, H.; Gress, R.; Sepkowitz, K.; Storek, J.; Wingard, J.R.; Young, J-AH.; Boeckh, M.J. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol. Blood Marrow Transplant., 2009, 15(10), 1143-1238.
8. Couriel, D.; Caldera, H.; Champlin, R.; Komanduri, K. Acute graftversus-host disease: pathophysiology, clinical manifestations, and management. Cancer, 2004, 101(9), 1936-1946.
9. Perl, T.M.; Chotani, R.; Agawala, R. Infection control and prevention in bone marrow transplant patients. In: Hospital Epidemiology and Infection Control, Mayhall CG Ed., 2nd ed.;. Lippincott Williams and Willkins: Philadelphia, 1999; pp.803-844.
10. Dettenkofer, M.; Ebner, W.; Bertz, H.; Babikir, R.;, Finke, J.; Frank, U.; Rüden, H.; Daschner, F.D. Surveillance of nosocomial infections in adult recipients of allogeneic and autologous bone marrow and peripheral blood stem-cell transplantation. Bone Marrow Transplant., 2003, 31, 795-801.
11. Centers for Disease Control and Prevention (CDC). West Nile virus transmission via organ transplantation and blood transfusion-Louisiana, 2008. M.M.W.R. Morb. Mortal. Wkly. Rep., 2009, 58(45), 1263-1267.
12. Schreiber, G.B.; Busch, M.P.; Kleinman, S.H.; Korelitz, J.J.The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N. Engl. J. Med., 1996, 334(26), 1685-1690.
13. Kikuchi, H.; Ohtsuka, E.; Nakayam, T.;, Saburi, Y.; Tezono, K.; Ogata, M.; Iwahashi, M.; Nasu, M. Allogeneic bone marrow transplantation-related transmission of human T lymphotropic virus type 1 (HTLV-1). Bone Marrow Transplant., 2000, 26(11), 1235-1237.
14. Shuhart, M.C.; Myerson, D.; Childs, B.H.; Fingeroth, J.D.; Perry, J.J.; Snyder, D.S., Spurgeon, C.L.; Bevan, C.A.; Mcdonald, G.B. Marrow transplantation from hepatitis C virus seropositive donors: transmission rate and clinical course. Blood, 1994, 84(9), 3229-3235.
15. Food and Drug Administration. Guidance for Industry: Eligibility Determination for Donors of Human Cells, Tissues, and Cellularand Tissue-Based Products (HCT/Ps). Washington, DC: Department of Health and Human Services; 2007. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissu e/ucm073964.htm [Accessed December 2009].
16. Goldman, K.E. Dental management of patients with bone marrow and solid organ transplantation. Dent. Clin. North Am., 2006, 50(4), 659-676.
17. Majorana, A.; Schubert, M.M.; Porta, F.; Ugazio, A.G.; Sapelli, P.L. Oral Complications of pediatric hematopoietic cell transplantation: diagnosis and management. Supp. Care Cancer, 2000, 8(5), 353-365.
18. Kumar, D.; Chen, M.H.; Welsh, B.; Siegel, D.; Cobos, I.; Messner, H.A.; Lipton, J.; Humar, A. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients. Clin. Infect. Dis., 2007, 45, 1576-1582.
19. Meisel, R.; Kuypers, L.; Dirksen, U.; Schubert, R.; Gruhn, B.; Strauss, G.; Beutel, K.; Groll, A.H.; Duffner, U.; Blutters-Sawatzki, R.; Holter, W.; Feuchtinger, T.; Gruttner, H.P.; Schroten, H.; Zielen, S.; Ohmann, C.; Laws, H.J.; Dilloo, D.; Impfung von Kindern nach allogener Stammzelltransplantation (KAST) Study Group. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood, 2007, 109, 2322-2326.
20. Molrine, D.C.; Antin, J.H.; Guinan, E.C.; Soiffer, R.J.; MacDonald, K.; Malley, R.; Malinoski, F.; Trocciola, S.; Wilson, M.; Ambrosino, D.M. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood, 2003, 101, 831-836.
21. Marschall, J.; Mermel, L.A.; Classen, D.; Arias, K.M.; Podgorny, K.; Anderson, D.J.; Burstin, H.; Calfee, D.P.; Coffin, S.E., Dubberke, E.R.; Fraser, V.; Gerding D.N.; Griffin, F.A.; Gross, P.; Kaye, K.S.; Klompas, M.; Lo, E.; Nicolle, L.; Pegues, D.A.; Perl, T.M.; Saint, S.; Salgado, C.D.; Weinstein, R.A.; Wise, R.; Yokoe, D.S. Strategies to prevent central line-associated bloodstream infections in acute care hospitals. Infect. Control Hosp. Epidemiol., 2008, 29(Suppl. 1), S22-S30.
22. Pittet, D.; Tarara, D.; Wenzel, R.P. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs and attributable mortality. J. Am. Med. Assoc., 1994, 271, 1598-1601.
23. Kim, D.H.; Bae, N.Y.; Sungy, W.J.; Kim, J.G., Kim, S.W.; Sohn, S.K.; Lee, K.B. Hickman catheter site infections after allogeneic stem cell transplantation: single-center experience. Transplant. Proc., 2004, 36, 3203-3207.
24. Adler, A.; Yaniv, I.; Solter, E.; Frued, E.; Samra, Z.; Stein, J.; Levy, I. Catheter-associated bloodstream infections in pediatric hematology-oncology patients: factors associated with catheter removal and recurrence. J. Pediatr. Hematol. Oncol., 2006, 28, 23-28.
25. Pronovost, P.; Needham, D.; Berenholtz, S.; Sinopoli, D.; Chu, H.; Cosgrove, S.; Sexton, B.; Hyzy, R.; Welsh, R.; Roth, G.; Bander, J.; Kepros, J.; Goeschel, C. An intervention to decrease catheterrelated bloodstream infections in the ICU. N. Engl. J. Med., 2006, 355, 2725-2732.
26. Costello, J.M.; Morrow, D.F.; Graham, D.A.; Potter-Bynoe, G.; Sandora, T.J.; Laussen, P.C. Systematic intervention to reduce central line-associated bloodstream infection rates in a pediatric cardiac intensive care unit. Pediatrics, 2008, 121(5), 915-923.
27. Chatzinikolaou, I.; Hanna, H.; Graviss, L.; Chaiban, G.; Perego, C.; Arbuckle, R.; Champlin, R.; Darouiche, R.; Samonis, G.; Raad, I. Clinical experience with minocycline and rifampin-impregnated central venous catheters in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect. Control Hosp. Epidemiol., 2003, 24, 961-963.
28. Timsit, J.F.; Schwebel, C.; Bouadma, L.; Geffroy, A.; Garrouste-Orgeas, M.; Pease, S.; Herault, M.C., Haouache, H.; Calvino-Gunther, S.; Gestin, B.; Armand-Lefevre, L.; Leflon, V.; Chaplain, C.; Benali, A.; Francais, A.; Adrie, C.; Zahar, J.R., Thuong, M.; Arrault, X.; Croize, J.; Lucet J.C.; Dressing Study Group. Chlorhexidine-impregnated sponges and less frequent dressing changes for prevention of catheter-related infections in critically ill patients: a randomized controlled trial. J. Am. Med. Assoc., 2009, 301, 1231-1241.
29. Soothill, J.S.; Bravery, K.; Ho, A.; Macqueen, S.; Collins, J.; Lock, P. A fall in bloodstream infections followed a change to 2% chlorhexidine in 70% isopropanol for catheter connection antisepsis: A pediatric single center before/after study on a hemopoietic stem cell transplant ward. Am. J. Infect. Control, 2009, 37(8), 626-630.
30. Mossad, S.B.; Longworth, D.L.; Goormastic, M.; Serkey, J.M.; Keys, T.F.; Bolwell, B.J. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant., 1996, 18(2), 265-271.
31. Engels, E.A.; Ellis, C.A.; Supran, S.E.; Schmid, C.H.; Barza, M.; Schenkein, D.P,; Koc, Y.; Miller, K.B.; Wong, J.B. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin. Infect. Dis., 1999, 28, 256-266.
32. Bucaneve, G.; Micozzi, A.; Menichetti, F. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N. Engl. J. Med., 2005, 353, 977-987.
33. Klastersky, J. Chemoprophylaxis of Gram-negative infections in neutropenic patients. Eur. Urol., 1990, 17(Suppl 1), 40-45.
34. Cruciani, M.; Malena, M.; Bosco, O.; Nardi, S.; Serpelloni, G.; Mengoli, C. Reappraisal with meta-analysis of the addition of gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J. Clin. Oncol., 2003, 21, 4127-4137.
35. Sung, L.; Nathan, P.C.; Alibhai, S.M.; Tomlinson, G.A.; Beyene, J. Meta-analysis: effect of prophylactic hematopoietic colonystimulating factors on mortality and outcomes of infection. Ann. Intern. Med., 2007, 147, 400-411.
36. Sullivan, K.M.; Storek, J.; Kopecky, K.J.; Jocom, J.; Longton, G.; Flowers, M.; Siadak, M.; Nims, J.; Witherspoon, R.P.; Anasetti, C.; Appelbaum, F.R.; Bowden, R.A.; Buckner, C.D.; Crawford, S.W.; Deeg, H.J.; Hansen, J.A.; McDonald, G.B.; Sanders, J.E.; Storb, R. A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery. Biol. Blood Marrow Transplant., 1996, 2(1), 44-53.
37. Saral, R.; Burns, W.H.; Laskin, O.L.; Santos, G.W.; Lietman, P.S. Acyclovir prophylaxis of herpes-simplex-virus infection. N. Engl. J. Med., 1981, 305(2), 63-67.
38. Wade, J.C.; Newton, B.; Flournoy, N.; Meyers, J.D. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann. Intern. Med., 1984, 100(6), 823-828.
39. Spielberger, R.; Stiff, P.; Bensinger, W.; Gentile, T.; Weisdorf, D.; Kewalramani, T.; Shea, T.; Yanovich, S.; Hansen, K.; Noga, S.; McCarty, J.; LeMaistre, C.F.; Sung, E.C.; Blazar, B.R.; Elhardt, D.; Chen, M.G.; Emmanoulides, C. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N. Engl. J. Med., 2004, 351(25), 2590-2598.
40. Hensley, M.L.; Hagerty, K.L.; Kewalramani, T.; Green, D.M.; Meropol, N.J.; Wasserman, T.H.; Cohen, G.I.; Emami, B.; Gradishar, W.J.; Mitchell, R.B.; Thigpen, J.T.; Trotti, A.; von Hoff, D.; Schuchter, L.M. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J. Clin. Oncol., 2009, 27(1), 127-145.
41. Engelhard, D.; Cordonnier, C.; Shaw, P.J.; Parkalli, T.; Guenther, C.; Martino, R.; Dekker, A.W.; Prentice, H.G.; Gustavsson, A.; Nurnberger, W.; Ljungman, P.; Infectious Disease Working Party of the European Bone Marrow Transplantation (IDWP-EBMT). Early and late invasive pneumococcal infection following stem cell transplantation: a European Bone Marrow Transplantation survery. Br. J. Haematol., 2002, 117, 444-450.
42. Youssef, S.; Rodriquez, G.; Rolston KV,; Champlin, R.E.; Raad, I.I.; Safdar, A. Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients. Medicine (Baltimore), 2007, 86(2), 69-77.
43. Boeckh, M.; Kim, H.W.; Flowers, M.E.; Meyers, J.D.; Bowden, R.A Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation - a randomized double-blind placebo-controlled study. Blood, 2006, 107, 1800-1805.
44. Erard, V.; Guthrie, K.A.; Varley, C.; Heugel, J.; Wald, A.; Flowers, M.E.; Corey, L.; Boeckh, M. One-year acyclovir prophylaxis for preventing varicella-zoster virus disease after hematopoietic cell transplantation: no evidence of rebound varicella-zoster virus disease after drug discontinuation. Blood, 2007, 110(8) 3071-3077.
45. Schulster, L.; Chinn, R.Y. Guidelines for environmental infection control in health-care facilities. Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. M. M. W. R. Recomm. Rep., 2003, 52(RR-10), 1-42.
46. Pittet, D.; Hugonnet, S.; Harbarth, S.; Mourouga, P.; Sauvan, V.; Touveneau, S.; Perneger, T.V. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet, 2000, 356(9238), 1307-1312.
47. Siegel, J.D.; Rhinehart, E.; Jackson, M.; Chiarello, L.; Health Care Infection Control Practices Advisory Committee. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am. J. Infect. Control, 2007, 35(Suppl. 2), S65-S164.
48. Safdar, N.; Maki, D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, Enterococcus, Gram-Negative Bacilli, Clostridium difficile, and Candida. Ann. Intern. Med., 2002, 136, 834-844.
49. Shaw, B.E.; Boswell, T.; Byrne, J.L.; Yates, C.; Russell, N.H. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant., 2007, 39, 623-629.
50. Kato, N.; Tanaka, J.; Mori, A.; Tutumi, Y.; Yonezumi, M.; Chiba, K.; Kondo, T.; Toyoshima, N.; Ota, S.; Hashino, S.; Asaka, M.; Imamura, M. The risk of persistent carriage of methicillin-resistant Staphylococcus aureus in hematopoietic stem cell transplantation. Ann. Hematol., 2003, 82, 310-312.
51. Muto, C.A.; Jernigan, J.A.; Ostrowsky, B.E.; Richet, H.M.; Jarvis, W.R.; Boyce, J.M.; Farr, B.M. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect. Control Hosp. Epidemiol., 2003, 24(5), 362-386.
52. Siegel J, Rhinehart E, Jackson M, Chlarelle, L. Healthcare Infection Control Practices Advisory Committee. Management of multi-drug resistant organisms in healthcare settings, 2006.http://www.cdc.gov/ncidod/dhqp/pdf/ar/MDROGuideline2006.pdf.2006 [Accessed 1/10/10].
53. Association for Professionals in Infection Control and Epidemiology. Guide to the elimination of methicillin-resistant Staphylococcus aureus (MRSA) transmission in hospital settings. http://www.apic.org/Content/NavigationMenu/GovernmentAdvocacy/MethicillinResistantStaphylococcusAureusMRSA/Resources/MRSAguide.pdf. 2007 [Accessed 1/10/10].
54. Calfee, D.P,; Salgado, C.D.; Classen, D.; Arias, K.M.; Podgorny, K.; Anderson, D.J.; Burstin, H.; Coffin, S.E.; Dubberke, E.R.; Fraser, V.; Gerding, D.N.; Griffin, F.A.; Gross, P.; Kaye, K.S.; Klompas, M.; Lo, E.; Marschall, J.; Mermel, L.A.; Nicolle, L.; Pegue, D.A.; Perl, T.M.; Saint, S.; Weintein R.A.; Wise, R.; Yokoe, D.S. Strategies to prevent transmission of methicillin-resistant Staphylococcus aureus in acute care hospitals. Infect. Control Hosp. Epidemiol., 2008, 29, S62-S80.
55. Avery, R.; Kalaycio, M.; Pohlman, B.; Sobecks, R.; Kuczkowski, E.; Andresen, S.; Mossad, S.; Shamp, J.; Curtis, J.; Kosar, J.; Sands, K.; Serafin, M.; Bolwell, B. Early vancomycin-resistant Enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant., 2005, 35, 497-499.
56. Weinstock, D.M.; Conlon, M.; Iovino, C.; Aubrey, T.; Gudiol, C.; Riedel, E.; Young, J.W.; Kiebn, T.E.; Zuccotti, G. Colonization, bloodstream infection, and mortality caused by vancomycinresistant Enterococcus early after allogeneic hematopoietic stem cell transplant. Biol. Blood Marrow Transplant., 2007, 13, 615-621.
57. Zirakzadeh, A.; Gastineau, D.A.; Mandrekar, J.N.; Burke, J.P.; Johnston, P.B.; Patel, R. Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant, 2008, 41, 385-392.
58. Oliveira, A.; de Souza, M.; Carvalho-Dias, V.M.H.; Ruiz, M.A.; Silla, L.; Tanaka, Y.; Simoes, B.P.; Trabasso, P.; Seber, A.; Lotfi, C.J.; Zanichelli, M.A.; Araujo, V.R.; Godoy, C.; Maiolino, A.; Urakawa, P.; Cunha, C.A.; de Souza, C.A.; Pasquini, R.; Nucci, M. Epidemiology of bacteremia and factors associated with multi-drugresistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Bone Marrow Transplant., 2007, 39, 775-781.
59. Garnica, M.; Maiolino, A.; Nucci, M. Factors associated with bacteremia due to mulitdrug-resistant gram-negative bacilli in hematopoietic stem cell transplant recipients. Braz. J. Med. Biol. Res., 2009, 42, 289-293.
60. Bobak, D.; Arfons, L.M.; Creger, R.J.; Lazarus, H.M. Clostridium difficile-associated disease in human stem cell transplant recipients: coming epidemic or false alarm?. Bone Marrow Transplant, 2008, 42, 705-713.
61. Muto, C.A.; Pokrywka, M.; Shutt, K.; Mendelsohn, A.B.; Nouri, K.; Posey, K.; Roberts, T.; Croyle, K.; Krystokiak, S.; Patel-Brown, S.; Pasculle, A.W.; Paterson, D.L.; Saul, M.; Harrison, L.H. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol., 2005, 26, 273-280.
62. McDonald, L.C.; Killgore, G.E.; Thompson, A.; Owens, R.C. Jr.; Kazakova, S.V.; Sambol, S.P.; Johnson, S.; Gerding, D.N. An epidemic, toxic gene-variant strain of Clostridium difficile. N. Engl. J. Med., 2005, 353, 4233-4241.
63. Arango, J.I.; Restrepo, A.; Schneider, D.L.; Callander, N.S.; Ochoa-Bayona, J.L.; Restrepo, M.I.; Bradshaw, P.; Patterson, J.; Freytes, C.O. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant., 2006, 37, 517-521.
64. Chakrabarti, S.; Lees, A.; Jones, S.G.; Miiligan, D.W. Clostridium difficile infection in allogeneic stem cell transplant recipients is associated with severe graft-versus-host disease and non-relapse mortality. Bone Marrow Transplant., 2000, 26, 871-876.
65. Dubberke, E.R.; Reske, K.A.; Srivastava, A.; Sadhu, J.; Gatti, R.; Young, R.M.; Rakes, L.C.; Dieckgraefe, B.; DiPersio, J.; Fraser, V.J. Clostridium difficile-associated disease in allogeneic hematopoitic stem-cell transplant recipients: risk associations, protective associations, and outcomes. Clin. Transplant., 2009;e-pub ahead of print http://www3.interscience.wiley.com.ezproxy.musc.edu/cgibin/fulltext/122511912/PDFSTART [Accessed 1/10/2010].
66. Salgado, C.D.; Mauldin, P.D.; Fogle, P.L.; Bosso, J.A. Analysis of an outbreak of Clostridium difficile infection controlled with enhanced infection control measures. Am. J. Infect. Control, 2009, 37(6), 458-464.
67. Muto, C.A.; Blank, M.K.; Marsh, J.W.; Vergis, E.N.; O'Leary, M.M.; Shutt, K.A.; Pasculle, A.W.; Pokrywka, M.G.; Garcia, J.G.; Posey, K.; Roberts, T.L.; Potoski, B.A.; Blank, G.E.; Simmons, R.L.; Veldkamp, P.; Harrison, L.H.; Paterson, D.L. Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive "bundle" approach. Clin. Infect. Dis., 2007, 45(10), 1266-1273.
68. Dubberke, E.R.; Gerding, D.N.; Classen, D.; Arias, K.M.; Podgorny, K.; Anderson, D.J.; Burstin, H.; Calfee, D.P.; Coffin, S.E.; Fraser, V.; Griffin, F.A.; Gross, P.; Kaye, K.S.; Klompas, M.; Lo, E.; Marschall, J.; Mermel, L.A.; Nicolle, L.; Pegues, D.A.; Perl, T.M.; Saint, S.; Salgado, C.D.; Weinstein, R.A.; Wise, R.; Yokoe, D.S. Strategies to prevent Clostridium difficile infection in acute care hospitals. Infect. Control Hosp. Epidemiol., 2008, 29(Suppl. 1), S81-92.
69. Hend, H.; Raad, I.; Gonzalez, V.; Umphrey, J.; Tarrand, J.; Neumann, J.; Champlin, R. Control of Nosocomial Clostridium difficile transmission in bone marrow transplant patients. Infect. Control Hosp. Epidemiol., 2000, 21, 226-228.